Gracell Biotechnologies Inc (NASDAQ:GRCL) stock gained momentum on Friday.
GRCL stock surged 20.70% to end the session at $17.61. More than 1.23 million shares traded hands – 12 X its 30-day average of 100K shares. The stock opened at $15.85 and moved within a wide range of $ 15.68 – 19.74.
GRCL Released News This Week
May 20, 2021 – Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021
- presenting updated results of their first-in-human multicenter study of GC012F for the treatment of relapsed and/or refractory multiple myeloma, a FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy currently in development for the treatment of multiple myeloma, at the 2021 American Society of Clinical Oncology (“ASCO”) Annual Meeting and the European Hematology Association 2021 (“EHA2021”) Congress.
- GC012F is a BCMA/CD19 dual-targeting CAR-T cell therapy developed on Gracell’s proprietary FasTCAR next-day manufacturing technology platform and is being evaluated in a Phase 1 investigator-initiated trial study.
|SHARES OUTSTANDING||19.81 M|
|SHARE FLOAT (%)||19.35 M –|
|% HELD BY INSTITUTIONS||97.88|
Recent Stock Performance
|+/- EMA(20)||12.91 (+36.41%)|
|+/- SMA(50)||14.91 (+18.11%)|
|+/- SMA(200)||19.36 (-9.04%)|
|Money Flow Index||23.9754||Sell||ROC||-4.9338||Sell|